Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
This facility will design & develop instruments, perform product reliability performance testing and verification
Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Within a fortnight, over 200 contestants sent their entries for the competition, and 30 names were shortlisted after screening entries under different categories
The main aim of the challenge is to encourage early-stage start-ups and individuals working on innovations in Ayurveda and other alternative healing and medicine systems
Subscribe To Our Newsletter & Stay Updated
